Neurosense Therapeutics is trading 5.42% lower at $4.19 in pre-market on October 1, 2026; no clear company-specific catalyst has been identified. - Shares closed September 30 at $4.43, down 7.32%, extending a steep pullback after declines in the prior two sessions. - The latest company update was published September 25; a September 28 analyst target increase was also reported, but neither clearly explains the decline. - Broader index futures were modestly higher, offering no clear explanation for the drop.